Update: A phase III trial of abiraterone has successfully been shown to increase average survival rate for men with advanced prostate cancer. The trial, funded by Janssen Pharmaceutical Companies, included 1195 patients from 13 countries. The average overall survival among the group who received abiraterone plus the steroid prednisone was 14.8 months, compared with 10.9 months for those who received the steroid and a placebo. People on abiraterone were more likely to experience a significant drop in their prostate-specific antigen (PSA) levels, the standard measure of prostate cancer activity, and saw an extended time in which tumour growth was halted.…
